Quick Answer
4D Molecular Therapeutics, Inc. reported Shares Outstanding of 57.61 million shares for fiscal year 2025.
4D Molecular Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 57.61M | +25.8% |
| 2024 | 45.79M | +6.3% |
| 2023 | 43.08M | +32.0% |
| 2022 | 32.63M | +1.2% |
| 2021 | 32.22M | +20.8% |
| 2020 | 26.68M | +415.2% |
| 2019 | 5.18M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 46.77M | -10.0% | +0.2% |
| June 30, 2025 | 46.70M | -10.0% | +0.8% |
| March 31, 2025 | 46.32M | -9.4% | +1.2% |
| December 31, 2024 | 45.79M | +6.3% | -11.9% |
| September 30, 2024 | 52.00M | +21.6% | +0.2% |
| June 30, 2024 | 51.91M | +23.6% | +1.5% |
| March 31, 2024 | 51.16M | +53.9% | +18.8% |
| December 31, 2023 | 43.08M | +32.0% | +0.8% |
- 4D Molecular Therapeutics, Inc. showed an increase of +25.8% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, 4D Molecular Therapeutics, Inc.’s shares outstanding has grown by 1012.3% (from 5.18 million shares to 57.61 million shares).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: